Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy, challenger from Massachusetts biotech Dyne ...
Jada Bafus told Page Six that she and the actress quickly came to realize it was a case of “two triggered mothers” having a ...
Capricor Therapeutics said Wednesday that its cell therapy significantly improved muscle and heart function in patients with ...
The Muscular Dystrophy Association (MDA) today announced more than $2.7 million in new research grants to advance groundbreaking discoveries across multiple neuromuscular diseases, including ...
Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.
Investor's Business Daily on MSN
Capricor Skyrockets 535% After Getting Vindication In Muscular Dystrophy
Capricor stock skyrocketed to an eight-year high Wednesday on positive results for its Duchenne muscular dystrophy treatment.
Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of ...
Find out if it’s time to ask about your child’s symptoms — and if they could be a sign of Duchenne. Duchenne muscular dystrophy — sometimes referred to simply as Duchenne — is a genetic disorder that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback